This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Validity of estimate of measure of effectiveness
The clinical evidence came from a review of the literature. Some information on the methods used to conduct the review was reported. For example, inclusion criteria were stated and the sources searched were given. All clinical data came from RCTs, which ensure a high internal validity. A published meta-analysis was also used. The method used to pool the primary estimates of treatment efficacy was reported. The issue of homogeneity across the primary studies was addressed and the result of the heterogeneity test was reported for all clinical end points. Several assumptions were made. The issue of uncertainty surrounding key clinical data was extensively tested in the sensitivity analysis. The clinical end points used in the analysis were typical outcome measures used for patients with hypertension.
Validity of estimate of measure of benefit
No summary benefit measure was used in the analysis because a cost-minimisation analysis was conducted. Please refer to the comments in the 'Validity of estimate of measure of effectiveness' field (above).
Validity of estimate of costs
The cost analysis was consistent with the stated perspective. A strength of the analysis was the inclusion of costs associated with side effects and switching. The authors stated that the adoption of a broader perspective, such as that of society, would not have substantially changed their conclusions. The unit costs and the quantities of resources used were presented separately, which enhances the possibility of replicating the analysis in other settings. The source of the data was reported for all items. Discounting was applied and the impact of using alternative discount rates was investigated. The costs were treated deterministically, but most cost estimates were varied in the sensitivity analysis. The price year was explicitly stated, which aids reflation exercises in other time periods.
Other issues
The authors did not report the results from other studies, but it was noted that the current findings are consistent with those from other economic evaluations. The issue of the generalisability of the study results to other settings was explicitly addressed. The authors pointed out that, despite variability in drug prices across countries, the relative difference in costs observed using Greek prices was similar to the cost-difference in the USA. Thus, it might be possible to extrapolate the results of the current study to other settings. Sensitivity analyses were performed on key estimates, and these further enhanced the external validity of the results of the analysis. The study referred to patients with uncomplicated hypertension and this was reflected in the authors' conclusions. Some limitations of the analysis were also noted. For example, the impact of the treatments on quality of life was not investigated, although the authors stated that RCTs had failed to show statistically significant differences in quality of life between treatment groups.
Implications of the study
The study results supported the use of older hypertensive agents as first-line treatment for uncomplicated hypertension.
Source of funding
None stated. 
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